Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review
Hye Kyu Min,Sooji Lee,Soeun Kim,Yejun Son,Jaeyu Park,Hyeon Jin Kim,Jinseok Lee,Hayeon Lee,Lee Smith,Masoud Rahmati,Jiseung Kang,Nikolaos G. Papadopoulos,Seong H. Cho,Jong Woo Hahn,Dong Keon Yon
DOI: https://doi.org/10.1111/cea.14592
2024-11-09
Clinical & Experimental Allergy
Abstract:Objective Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden. Design We conducted a systematic review and meta‐analysis of general population‐based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions. Data Sources PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases. Eligibility Criteria for Selection We included general population‐based observational studies on CRS published from database inception through October 20, 2023. Results A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69–11.33; number of studies, 20) and 0.65% (95% CI, 0.56–0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never‐smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980–2000: 4.72%; 95% CI, 2.12–10.49; 2014–2020: 19.40%; 95% CI, 12.12–31.07). Similar patterns were observed in CRS incidence. Conclusions Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative. Systematic Review Registration PROSPERO (registration no. CRD42024527805).
immunology,allergy